BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

MediGene, Inc. To Present At The Biotechnology Industry Organization (BIO) CEO & Investor Conference In New York


10/19/2005 5:12:44 PM

MARTINSRIED and MUNICH, Germany and SAN DIEGO, Feb. 15 /PRNewswire- FirstCall/ -- The German-American biotech company MediGene AG (Frankfurt, Prime Standard: MDG) [MDGGn.DE] announced today that the company will be presenting at the BIO CEO & Investor Conference in New York, on February 24, at 3.00 p.m. local time, at the Waldorf Astoria Hotel. Dr. Peter Heinrich, Chief Executive Officer of MediGene AG, will give a review of the company and update the audience on current clinical and business developments. The presentation will be available on the internet at http://www.medigene.com/ from February 24 on.

MediGene possesses a mature drug pipeline with a drug available on the European market (Eligard(R) for the treatment of prostate cancer) and several drug candidates, undergoing all stages in clinical development (phases I-III), such as Polyphenon(R) E Ointment for the treatment of skin tumors which has recently completed clinical phase III. In addition, MediGene owns cutting-edge platform technologies with the HSV as well as the recently acquired EndoTAG technologies. The EndoTAG drug candidates utilize the already approved and applied therapy of anti-angiogenesis (suppressing tumor vascularization), while adding another, novel mode of action: the innovative carrier system of lipid complexes allows a novel application method of established cytostatic drugs (e.g. Taxane), intended to cause the selective attachment to and destruction of tumor blood vessels ("neovascular targeting"). The drug candidate EndoTAG-1 has already undergone several clinical phase I trials in various cancer diseases. In 2005, MediGene is planning to initiate a number of phase II trials of EndoTAG-1 in two cancer indications.

This press release contains forward-looking statements that involve risks and uncertainties. The forward-looking statements contained herein represent the judgement of MediGene as of the date of this release. These forward-looking statements are no guarantees for future performance, and the forward-looking events discussed in this press release may not occur. MediGene disclaims any intent or obligation to update any of these forward-looking statements. MediGene(TM) is a trademark of MediGene AG, Eligard(R) is a trademark of QLT USA, Inc. (formerly Atrix), Polyphenon(R) E is a trademark of Mitsui Norin.

MediGene AG

CONTACT: Dr. Michael Nettersheim, Investor Relations, +49-89-85-65-2946,or Julia Hofmann, Corporate Communications, +49-89-85-65-3324, both ofMediGene AG, investor@medigene.com, or fax, +49-89-85-65-2920



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES